Tuparstobart
Phase 2Small molecule
Tuparstobart is one of 2 small molecule programs targeting Clinical Stage III Merkel Cell Carcinoma AJCC v8. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Clinical Stage III Merkel Cell Carcinoma AJCC V8
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tuparstobart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Washington